Cargando…

1897. Letermovir Salvage for Complicated Cases of Resistant CMV

BACKGROUND: Limited treatment options exist for ganciclovir-resistant CMV disease. Foscarnet can cause renal insufficiency, and maribavir has poor ocular penetration. Letermovir is approved for primary CMV prophylaxis in hematopoietic stem cell transplantation, but efficacy in treatment of CMV disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turner, Nicholas, Strand, Andrew, Saullo, Jennifer, Arif, Sana, Maziarz, Eileen K, Grewal, Dilraj, Baker, Arthur W, Wolfe, Cameron R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253476/ http://dx.doi.org/10.1093/ofid/ofy210.1553

Ejemplares similares

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
por: Di Cristanziano, Veronica, et al.
Publicado: (2021)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

1758. Epidemiology of Invasive Mycoplasma and Ureaplasma Infections Early after Lung Transplantation
por: Baker, Arthur W, et al.
Publicado: (2019)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

2296. Development of a Sequencing-Based Assay for Detection of CMV Antiviral Resistance Mutations to Letermovir in UL56
por: Grantham, James, et al.
Publicado: (2018)

1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients
por: Abidi, Maheen, et al.
Publicado: (2020)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

194. Combinatorial Polyfunctionality Analysis of Antigen-specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era
por: Zamora, Danniel, et al.
Publicado: (2020)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

641. Limited Utility of Epstein-Barr Virus (EBV) Surveillance for Predicting Post-Transplant Lymphoproliferative Disorder in EBV Seropositive Adult Lung Transplant Recipients
por: Heldman, Madeleine R, et al.
Publicado: (2023)

Welcome, 1897
Publicado: (1896)

1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience
por: Zavras, Phaedon D, et al.
Publicado: (2019)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2022)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

1897: A Retrospect
Publicado: (1898)

Annual Address, 1897
por: Truman, James
Publicado: (1897)

Medical Matters in 1897
Publicado: (1898)

1897—Journal—1898
Publicado: (1897)

Nashville the Mecca for 1897
Publicado: (1897)

CMV hyperimmune globulin as salvage therapy for recurrent or refractory CMV infection in children undergoing hematopoietic stem cell transplantation
por: Panesso, Melissa, et al.
Publicado: (2023)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

The Bill for the Registration of Midwives, 1897
Publicado: (1897)

Zymotic Death-Rates in 1897
Publicado: (1898)

The Workmen's Compensation Act, 1897
Publicado: (1898)

Adam Opalski (1897–1963)
por: Rytel, Liliana, et al.
Publicado: (2017)

The Inebriates Acts, 1897-1900
Publicado: (1907)

The Physician’s Visiting List for 1897
Publicado: (1897)

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study
por: Han, Gyuri, et al.
Publicado: (2021)

LB2307. Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study
por: Limaye, Ajit P, et al.
Publicado: (2022)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e452dde66us84sh8fnpm65snr0